Vitiligo-like lesions in patients receiving anti–programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo

Katia Boniface(Université de Bordeaux), Julien Sénéschal(Hôpital Saint-André), S. Prey(Université de Bordeaux), Alain Taı̈eb(Université de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux)
Journal of the American Academy of Dermatology
December 12, 2017
10.1016/j.jaad.2017.08.028
Cited by 16

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k